tirzepatide lilly precio launches lower-price weight-loss drug Zepbound without injector pen Eli Lilly cuts Zepbound prices
Description
Retatrutide demonstrated 24.2% body weight reduction in Phase 2 trials, approaching bariatric surgery outcomes
The single use pens may be kept at room temperature for up to 21 days
*In a 72-week study of adults without diabetes, average weight loss was 15.0% (34 lbs) for 5mg, 19.5% (44 lbs) for 10mg, 20.9% (48 lbs) for 15 mg, and 3.1 (7 lbs) for placebo
They can monitor the situation and provide guidance on how to alleviate any discomfort and prevent potential complications
Front Med (Lausanne) (2022) 9:875430
